Skip to content
Markets News
Markets2 min read

Apollo Circles J&J’s DePuy Synthes in $20 Billion Deal

Makkler Newsroom
September 16, 2026 · Based on reporting by Quartz

The potential sale would accelerate J&J’s portfolio reshaping while giving Apollo a major foothold in orthopedic medical devices.

A $20 billion price tag would put Johnson & Johnson’s DePuy Synthes orthopedics business at roughly 2.1 times its reported annual sales, a valuation that reflects both the unit’s scale and the scarcity of large medical-device assets.

Apollo Global Management is in non-binding talks to acquire the business for close to $20 billion, according to Bloomberg, with an agreement possible within weeks. The discussions may still collapse, and other private-equity bidders have shown interest. J&J could also pursue a public-market separation instead.

DePuy Synthes generated about $9.3 billion in sales last year, according to reports. Its portfolio spans hip and knee replacements, trauma products, spine implants, sports medicine and surgical tools. J&J has described the unit as potentially the world’s largest standalone orthopedics company, serving roughly seven million patients annually across a market worth more than $50 billion.

The talks build on a restructuring plan J&J announced in October 2025. The company said it intended to separate DePuy Synthes within 18 to 24 months, allowing the remaining MedTech business to concentrate on faster-growing areas such as cardiovascular devices, surgery and vision. J&J has said the separation is targeted for completion by mid-2027.

Chief Financial Officer Joseph Wolk said in July that the company was evaluating every separation route capable of creating shareholder value and positioning DePuy Synthes for long-term growth. That leaves a sale, a spin-off or another structure on the table until a final decision is made.

For Apollo, the transaction would be a sizable deployment into a business with recurring hospital demand, established surgeon relationships and a broad installed product base. The firm’s private-equity operation reported $70 billion in assets under management as of June 30, 2026, and has emphasized corporate carve-outs as a core strategy.

The deal would also mark a sharp change in ownership for a franchise J&J built through the $20.2 billion acquisition of Synthes in 2012. Apollo would inherit the operational challenge that J&J is trying to isolate: turning a sprawling global device portfolio into a more focused company with stronger growth and margins.

J&J shares were little changed at $265.58 in Friday trading, while Apollo rose 0.8% to $128.98, according to Bloomberg.

Topics
JNJAPODePuy Synthes
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.